The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.2M data for 1.4M Compounds and 11.4K Targets. Of those, 1.6M data for 748K Compounds and 4.8K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

To help with training and testing AI and other models, BindingDB downloads and search results now provide the publication date and BindingDB curation date of each measurement.

8 articles for M Ohlmeyer


The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
Reengineered tricyclic anti-cancer agents.EBI
Icahn School of Medicine At Mt. Sinai
Structure-guided design of potent diazobenzene inhibitors for the BET bromodomains.EBI
Icahn School Of Medicine At Mount Sinai
Discovery of potent, soluble and orally active TRPV1 antagonists. Structure-activity relationships of a series of isoxazoles.EBI
Merck Research Laboratories
Discovery and optimisation of a selective non-steroidal glucocorticoid receptor antagonist.EBI
Merck Research Laboratories
Structure-activity studies of a novel series of isoxazole-3-carboxamide derivatives as TRPV1 antagonists.EBI
Merck Sharpe and Dohme
Triazine and pyrimidine based ROCK inhibitors with efficacy in spontaneous hypertensive rat model.EBI
Ligand Pharmaceuticals
Design, synthesis, and activity of 2-imidazol-1-ylpyrimidine derived inducible nitric oxide synthase dimerization inhibitors.EBI
Berlex Biosciences
Imidazolylpyrimidine based CXCR2 chemokine receptor antagonists.EBI
Pharmacopeia Drug Discovery